Treatment Patterns, Inadequate Disease Control, and Burden/Unmet Need Among Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program
Author(s)
Jonathan I. Silverberg, MD, PhD, MPH1, Kimberly M Deininger, PhD, MPH2, Alexis Sohn, MPH, MS, PharmD2, Joyce Qian, PhD, MPH, MS3, James Piercy, MSc, PhD4, Oliver Howell, BSc4, Corey Moorhead, BSc4, Peter Anderson, BSc4.
1Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Kyowa Kirin Inc., 510 Carnegie Center, Suite 600, Princeton, NJ, USA, 4Adelphi Real World, Bollington, United Kingdom.
1Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Kyowa Kirin Inc., 510 Carnegie Center, Suite 600, Princeton, NJ, USA, 4Adelphi Real World, Bollington, United Kingdom.
OBJECTIVES: Describe treatment patterns, disease control and burden in patients with moderate-to-severe atopic dermatitis (msAD) across US/Europe (France/Germany/Italy/Spain/United Kingdom).
METHODS: Data from the Adelphi AD Disease Specific ProgrammeTM, a cross-sectional survey of physicians and their patients with AD in US/Europe, collected August 2022-April 2024, were analysed retrospectively. Patients with physician-assessed msAD were included. Physician-reported demographics, treatment patterns, and clinical characteristics were assessed.
RESULTS: A total of 675 physicians provided data for 1484 msAD patients (mean [SD] age 37.3 [15.5], 52% male). Mean disease duration (n=780) was 6.1 [8.9] years. Among currently treated patients (n=1418), 48% initiated treatment due to a flare; 76% received topical corticosteroids (TCS) and 26% received advanced systemic therapy (AST, i.e. biologic/oral JAK inhibitor). For first (n=1082), second (n=525), and third line (n=218) physician-reported treatment regimens, 79%/65%/71% of patients received TCS, and 11%/20%/28% received AST, respectively. For patients who have experienced flares and been on any current treatment for ≥3months (n=302), 54% and 45% had no improvement in flare frequency or severity, respectively; and this was true for 35% and 30% of patients receiving AST for that period (n=79). Among patients experiencing day-to-day symptoms (n=222), moderate-to-severe pruritus (87%), skin pain (64%), hyperpigmentation (37%), and sleep disturbance (32%) were reported at consultation; for AST patients (n=50) these were 84%/46%/34%/44%, respectively. For 30% of patients who switched treatment, lack of long-term control was reported as a reason for switching. Physicians also reported long-term control as a main goal of current treatment for 53% of patients.
CONCLUSIONS: Current treatment patterns suggest reactive prescribing in response to flares. However, nearly half of patients experienced no improvement in flare frequency or severity, and symptomatic burden remained high after receiving at least 3 months current therapy, even in patients receiving AST. Long-term control is a key treatment goal for msAD that is frequently not met.
METHODS: Data from the Adelphi AD Disease Specific ProgrammeTM, a cross-sectional survey of physicians and their patients with AD in US/Europe, collected August 2022-April 2024, were analysed retrospectively. Patients with physician-assessed msAD were included. Physician-reported demographics, treatment patterns, and clinical characteristics were assessed.
RESULTS: A total of 675 physicians provided data for 1484 msAD patients (mean [SD] age 37.3 [15.5], 52% male). Mean disease duration (n=780) was 6.1 [8.9] years. Among currently treated patients (n=1418), 48% initiated treatment due to a flare; 76% received topical corticosteroids (TCS) and 26% received advanced systemic therapy (AST, i.e. biologic/oral JAK inhibitor). For first (n=1082), second (n=525), and third line (n=218) physician-reported treatment regimens, 79%/65%/71% of patients received TCS, and 11%/20%/28% received AST, respectively. For patients who have experienced flares and been on any current treatment for ≥3months (n=302), 54% and 45% had no improvement in flare frequency or severity, respectively; and this was true for 35% and 30% of patients receiving AST for that period (n=79). Among patients experiencing day-to-day symptoms (n=222), moderate-to-severe pruritus (87%), skin pain (64%), hyperpigmentation (37%), and sleep disturbance (32%) were reported at consultation; for AST patients (n=50) these were 84%/46%/34%/44%, respectively. For 30% of patients who switched treatment, lack of long-term control was reported as a reason for switching. Physicians also reported long-term control as a main goal of current treatment for 53% of patients.
CONCLUSIONS: Current treatment patterns suggest reactive prescribing in response to flares. However, nearly half of patients experienced no improvement in flare frequency or severity, and symptomatic burden remained high after receiving at least 3 months current therapy, even in patients receiving AST. Long-term control is a key treatment goal for msAD that is frequently not met.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD116
Topic
Health Service Delivery & Process of Care
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)